PHYSICIANS REALTY TRUST (a Maryland real estate investment trust) 15,000,000 Common Shares of Beneficial Interest UNDERWRITING AGREEMENT March 13, 2017 Morgan Stanley & Co. LLC KeyBanc Capital Markets Inc. Merrill Lynch, Pierce, Fenner & Smith...
![Page 1](https://www.sec.gov/Archives/edgar/data/1583994/000157454017000044/exhibit11finalunderwriti001.jpg)
Exhibit 1.1
Dated: March 13, 2017
PHYSICIANS REALTY TRUST
(a Maryland real estate investment trust)
15,000,000 Common Shares Of Beneficial Interest
UNDERWRITING AGREEMENT
![Page 2](https://www.sec.gov/Archives/edgar/data/1583994/000157454017000044/exhibit11finalunderwriti002.jpg)
PHYSICIANS REALTY TRUST
(a Maryland real estate investment trust)
15,000,000 Common Shares of Beneficial Interest
UNDERWRITING AGREEMENT
March 13, 2017
Xxxxxx Xxxxxxx & Co. LLC
KeyBanc Capital Markets Inc.
Xxxxxxx Lynch, Pierce, Xxxxxx & Xxxxx
Incorporated
as Representatives of the several Underwriters
c/o Morgan Xxxxxxx & Co. LLC
0000 Xxxxxxxx
Xxx Xxxx, Xxx Xxxx 00000
c/o KeyBanc Capital Markets Inc.
000 Xxxxxx Xxxxxx
0xx Xxxxx
Xxxxxxxxx, Xxxx 00000
c/o Merrill Lynch, Pierce, Xxxxxx & Xxxxx
Incorporated
Xxx Xxxxxx Xxxx
Xxx Xxxx, Xxx Xxxx 00000
Ladies and Gentlemen:
Physicians Realty Trust, a Maryland real estate investment trust (the “Company”), and
Physicians Realty L.P., a Delaware limited partnership (the “Operating Partnership”), confirm
their agreement with Xxxxxx Xxxxxxx & Co. LLC (“Xxxxxx Xxxxxxx”), KeyBanc Capital Markets
Inc. (“KeyBanc”) and Xxxxxxx Lynch, Pierce, Xxxxxx & Xxxxx Incorporated (“Xxxxxxx Xxxxx”),
and each of the other Underwriters named in Schedule A hereto (collectively, the
“Underwriters,” which term shall also include any underwriter substituted as hereinafter
provided in Section 10 hereof), for whom Xxxxxx Xxxxxxx, KeyBanc and Xxxxxxx Xxxxx are
acting as representatives (in such capacity, the “Representatives”), with respect to (i) the sale by
the Company and the purchase by the Underwriters, acting severally and not jointly, of the
respective numbers of common shares of beneficial interest, par value $0.01 per share, of the
Company (“Common Shares”) set forth in Schedule A hereto and (ii) the grant by the Company
![Page 3](https://www.sec.gov/Archives/edgar/data/1583994/000157454017000044/exhibit11finalunderwriti003.jpg)
to the Underwriters, acting severally and not jointly, of the option described in Section 2(b)
hereof to purchase all or any part of 2,250,000 additional Common Shares. The aforesaid
15,000,000 Common Shares (the “Initial Securities”) to be purchased by the Underwriters and all
or any part of the 2,250,000 Common Shares subject to the option described in Section 2(b)
hereof (the “Option Securities”) are herein called, collectively, the “Securities.”
The Company understands that the Underwriters propose to make a public offering of the
Securities as soon as the Representatives deem advisable after this underwriting agreement (this
“Agreement”) has been executed and delivered.
The Company and the Operating Partnership have filed with the Securities and Exchange
Commission (the “Commission”) an “automatic shelf registration statement” under the Securities
Act of 1933, as amended (the “1933 Act”), on Form S-3ASR (No. 333-216214), including a base
prospectus, covering the registration of certain securities, including the Securities, under the 1933
Act and the rules and regulations promulgated thereunder (the “1933 Act Regulations”), each of
which became effective upon filing under Rule 462(e) under the 1933 Act Regulations (“Rule
462(e)”). Such registration statement, at any given time, means such registration statement, as
amended by any post-effective amendments thereto at such time, including the exhibits and any
schedules thereto at such time, the documents incorporated or deemed to be incorporated by
reference therein pursuant to Item 12 of Form S-3 under the 1933 Act at such time, and the
information and documents otherwise deemed to be a part thereof pursuant to Rule 430B under
the 1933 Act Regulations (“Rule 430B”), including any prospectus supplement relating to the
Securities that is filed with the Commission pursuant to Rule 424(b) of the 1933 Act Regulations
(“Rule 424(b)”) at such time, is referred to herein as the “Registration Statement.”
Each preliminary prospectus, including the base prospectus and each preliminary
prospectus supplement, related to the offering of the Securities and filed with the Commission
pursuant to Rule 424(b), including the documents incorporated or deemed to be incorporated by
reference therein pursuant to Item 12 of Form S-3 under the 1933 Act, are collectively referred to
herein as a “preliminary prospectus.” Promptly after execution and delivery of this Agreement,
the Company will prepare and file a final prospectus relating to the Securities in accordance with
the provisions of Rule 424(b) under the 1933 Act. The final prospectus, including the base
prospectus and the final prospectus supplement, in the form first furnished or made available to
the Underwriters for use in connection with the offering of the Securities, including the documents
incorporated or deemed to be incorporated by reference therein pursuant to Item 12 and of Form
S-3 under the 1933 Act, are collectively referred to herein as the “Prospectus.” For purposes of
this Agreement, all references to the Registration Statement, any preliminary prospectus, the
Prospectus or any amendment or supplement to any of the foregoing shall be deemed to include
the copy filed with the Commission pursuant to its Electronic Data Gathering, Analysis and
Retrieval system or any successor system (“XXXXX”).
As used in this Agreement:
“Applicable Time” means 7:04 p.m., New York City time, on March 13, 2017.
“General Disclosure Package” means any Issuer General Use Free Writing
Prospectuses issued at or prior to the Applicable Time, the most recent preliminary prospectus
![Page 14](https://www.sec.gov/Archives/edgar/data/1583994/000157454017000044/exhibit11finalunderwriti014.jpg)
subsidiaries has received written notice of proposed material special assessment or any
proposed change in any property tax, zoning or land use law or availability of water
affecting any Property that would reasonably be expected to result in a Material Adverse
Effect. Except as described in the Registration Statement, the General Disclosure Package
and the Prospectus, the Company or one or more of its subsidiaries has obtained, on or
prior to the date hereof, one or more title insurance policies on, whether directly or through
assignment or endorsements, or a so-called “fairway-endorsement” on existing title
policies covering, the fee interests (or leasehold interests as the case may be) from a
nationally recognized title insurance company, or, if such title policy has not been issued,
a binding commitment by such title insurance company to issue such a policy, which
policies include commercially reasonable exceptions, with coverage in such amounts as
are commercially reasonable for the assets owned or leased by the Company and that are
consistent with the types and amounts of insurance typically maintained by owners of
similar properties, and such title insurance policies, fairway endorsements or binding
commitments, as the case may be, are in full force and effect in all material respects. Except
as would not, individually or in the aggregate reasonably be expected to result in a Material
Adverse Effect, there are no encroachments upon any Property by improvements on an
adjacent property, and none of the improvements on any Property encroach on any adjacent
property, streets or alleys. Except as set forth in the Registration Statement, the General
Disclosure Package and the Prospectus, neither the Company nor any of its subsidiaries is
a party to any material lease that is required to be disclosed in the Registration Statement
or the Prospectus. Except as set forth in the Registration Statement, the General Disclosure
Package and the Prospectus, neither the Company nor any of its subsidiaries holds any
Property under a ground lease, and true and complete copies of each ground lease described
in the Registration Statement, the General Disclosure Package and the Prospectus have
been provided to the Underwriters or their counsel. To the knowledge of the Company and
the Operating Partnership, all real property owned or leased by the Company or a
Subsidiary is free of material structural defects and all building systems contained therein
are in good working order in all material respects, subject to ordinary wear and tear or, in
each instance, the Company has created an adequate reserve to effect reasonably required
repairs, maintenance and capital expenditures; to the knowledge of the Company and the
Operating Partnership, water, storm water, sanitary sewer, electricity and telephone service
are all available at the property lines of such property over duly dedicated streets or
perpetual easements of record benefiting such property; except as described in the
Registration Statement, the General Disclosure Package and the Prospectus, to the
knowledge of the Company and the Operating Partnership, there is no pending or
threatened special assessment, tax reduction proceeding or other action that, individually
or in the aggregate, could reasonably be expected to increase or decrease the real property
taxes or assessments of any of such property, that, individually or in the aggregate, would
reasonably be expected to have a Material Adverse Effect. To the knowledge of the
Company and the Operating Partnership, except as set forth in or described in the
Registration Statement, the General Disclosure Package and the Prospectus, including as
may be reflected in the pro forma financial statements, and except as would not,
individually or in the aggregate, reasonably be expected have a Material Adverse Effect:
(A) no rentals or other amounts due under any lease have been paid more than one (1)
month in advance; (B) no tenant has asserted in writing any defense or set-off against the
![Page 33](https://www.sec.gov/Archives/edgar/data/1583994/000157454017000044/exhibit11finalunderwriti033.jpg)
omissions which resulted in such losses, liabilities, claims, damages or expenses, as well as any
other relevant equitable considerations.
The relative benefits received by the Company and the Operating Partnership, on the one
hand, and the Underwriters, on the other hand, in connection with the offering of the Securities
pursuant to this Agreement shall be deemed to be in the same respective proportions as the total
net proceeds from the offering of the Securities pursuant to this Agreement (before deducting
expenses) received by the Company and the Operating Partnership, on the one hand, and the total
underwriting discount received by the Underwriters, on the other hand, in each case as set forth on
the cover of the Prospectus, bear to the aggregate public offering price of the Securities as set forth
on the cover of the Prospectus.
The relative fault of the Company and the Operating Partnership, on the one hand, and the
Underwriters, on the other hand, shall be determined by reference to, among other things, whether
any such untrue or alleged untrue statement of a material fact or omission or alleged omission to
state a material fact relates to information supplied by the Company and the Operating Partnership
or by the Underwriters and the parties’ relative intent, knowledge, access to information and
opportunity to correct or prevent such statement or omission.
The Company, the Operating Partnership and the Underwriters agree that it would not be
just and equitable if contribution pursuant to this Section 7 were determined by pro rata allocation
(even if the Underwriters were treated as one entity for such purpose) or by any other method of
allocation which does not take account of the equitable considerations referred to above in this
Section 7. The aggregate amount of losses, liabilities, claims, damages and expenses incurred by
an indemnified party and referred to above in this Section 7 shall be deemed to include any legal
or other expenses reasonably incurred by such indemnified party in investigating, preparing or
defending against any litigation, or any investigation or proceeding by any governmental agency
or body, commenced or threatened, or any claim whatsoever based upon any such untrue or alleged
untrue statement or omission or alleged omission.
Notwithstanding the provisions of this Section 7, no Underwriter shall be required to
contribute any amount in excess of the amount by which the total price at which the Securities
underwritten by it and distributed to the public exceeds the amount of any damages which such
Underwriter has otherwise been required to pay by reason of any such untrue or alleged untrue
statement or omission or alleged omission.
No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of
the 0000 Xxx) shall be entitled to contribution from any person who was not guilty of such
fraudulent misrepresentation.
For purposes of this Section 7, each person, if any, who controls an Underwriter within the
meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act and each Underwriter’s
Affiliates and selling agents shall have the same rights to contribution as such Underwriter, and
each trustee of the Company, each officer of the Company who signed the Registration Statement,
and each person, if any, who controls the Company or the Operating Partnership within the
meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act shall have the same rights to
contribution as the Company or the Operating Partnership. The Underwriters’ respective
![Page 38](https://www.sec.gov/Archives/edgar/data/1583994/000157454017000044/exhibit11finalunderwriti038.jpg)
If the foregoing is in accordance with your understanding of our agreement, please sign
and return to the Company a counterpart hereof, whereupon this instrument, along with all
counterparts, will become a binding agreement among the Underwriters, the Company and the
Operating Partnership in accordance with its terms.
Very truly yours,
PHYSICIANS REALTY TRUST
By /s/ Xxxx X. Xxxxxx ____________________
Name: Xxxx X. Xxxxxx
Title: President and Chief Executive Officer
PHYSICIANS REALTY L.P.
By: Physicians Realty Trust, its general partner
By /s/ Xxxx X. Xxxxxx ____________________
Name: Xxxx X. Xxxxxx
Title: President and Chief Executive Officer
![Page 39](https://www.sec.gov/Archives/edgar/data/1583994/000157454017000044/exhibit11finalunderwriti039.jpg)
CONFIRMED AND ACCEPTED,
as of the date first above written:
XXXXXX XXXXXXX & CO. LLC
By /s/ Xxx Xxxxxxx
Name: Xxx Xxxxxxx
Title: Executive Director
KEYBANC CAPITAL MARKETS INC.
By /s/ Xxxxxxxx X. Xxxxx
Name: Xxxxxxxx X. Xxxxx
Title: Sr. Managing Director
XXXXXXX LYNCH, PIERCE, XXXXXX & XXXXX
INCORPORATED
By /s/ Xxxx Xxxxxxx
Name: Xxxx Xxxxxxx
Title: Managing Director
For themselves and as Representatives of the other Underwriters named in Schedule A hereto.